Pandion’s immune-regulating platform attracts $80M B round

Pandion’s immune effectors can be mixed and matched with tissue-tethering antibodies, providing partnership opportunities across different diseases

Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with Boxer Capital.

Additional new investors RA Capital and OrbiMed Advisors also participated in the round, as did existing investors Polaris Partners, Versant

Read the full 567 word article

How to gain access

Continue reading with a
two-week free trial.